Details for Patent: 10,786,518

Which drugs does patent 10,786,518 protect, and when does it expire?

Patent 10,786,518 protects SYMTUZA and is included in one NDA.

This patent has ten patent family members in nine countries.

Summary for Patent: 10,786,518

Title:	Compositions and methods of treating HIV
Abstract:	The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.
Inventor(s):	Boven; Katia (Titusville, NJ), De Smedt; Goedele (Geel, BE), Driesen; Regina (Kessel, BE), Henrist; Dominiek (Zoersel, BE), Kauwenberghs; Greet (Schoten, BE), Mathur; Sandeep (Furlong, PA), McCallister; Scott (San Francisco, CA), Mertens; Roel (Balen, BE), Nettles; Richard (New Hope, PA), Opsomer; Magda (Sint-Pieters-Leeuw, BE), Pyrz; William (Belmont, CA), Zia; Vahid (Palo Alto, CA)
Assignee:	Janssen Sciences Ireland UC (Co Cork, IE) Gilead Sciences, Inc. (Foster City, CA)
Application Number:	16/040,324
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,786,518

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Prods	SYMTUZA	cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210455-001	Jul 17, 2018		RX	Yes	Yes						TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH = 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

International Family Members for US Patent 10,786,518

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018304373
Brazil	112020000842
Canada	3070713
Chile	2020000136
European Patent Office	3654951
Japan	2020528409